BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fawsitt CG, Vickerman P, Cooke G, Welton NJ; STOP-HCV Consortium. A Cost-Effectiveness Analysis of Shortened Direct-Acting Antiviral Treatment in Genotype 1 Noncirrhotic Treatment-Naive Patients With Chronic Hepatitis C Virus. Value Health 2019;22:693-703. [PMID: 31198187 DOI: 10.1016/j.jval.2018.12.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Walker JG, Kuchuloria T, Sergeenko D, Fraser H, Lim AG, Shadaker S, Hagan L, Gamkrelidze A, Kvaratskhelia V, Gvinjilia L, Aladashvili M, Asatiani A, Baliashvili D, Butsashvili M, Chikovani I, Khonelidze I, Kirtadze I, Kuniholm MH, Otiashvili D, Sharvadze L, Stvilia K, Tsertsvadze T, Zakalashvili M, Hickman M, Martin NK, Morgan J, Nasrullah M, Averhoff F, Vickerman P. Interim effect evaluation of the hepatitis C elimination programme in Georgia: a modelling study. Lancet Glob Health. 2020;8:e244-e253. [PMID: 31864917 DOI: 10.1016/s2214-109x(19)30483-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
2 Jones CR, Flower BF, Barber E, Simmons B, Cooke GS. Treatment optimisation for hepatitis C in the era of combination direct-acting antiviral therapy: a systematic review and meta-analysis. Wellcome Open Res 2019;4:132. [PMID: 31754636 DOI: 10.12688/wellcomeopenres.15411.1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
3 Thieneman C, Frederick E, Palmer E, Spencer C, Vories S, Maier C. Evaluation of cure rate in patients with hepatitis C virus completing shortened courses of treatment. J Am Pharm Assoc (2003) 2021:S1544-3191(21)00349-6. [PMID: 34454865 DOI: 10.1016/j.japh.2021.08.008] [Reference Citation Analysis]
4 Fawsitt CG, Vickerman P, Cooke GS, Welton NJ; STOP HCV Consortium. Cost-Effectiveness Analysis of Baseline Testing for Resistance-Associated Polymorphisms to Optimize Treatment Outcome in Genotype 1 Noncirrhotic Treatment-Naïve Patients With Chronic Hepatitis C Virus. Value Health 2020;23:180-90. [PMID: 32113623 DOI: 10.1016/j.jval.2019.08.012] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Cooke GS, Pett S, McCabe L, Jones C, Gilson R, Verma S, Ryder SD, Collier JD, Barclay ST, Ala A, Bhagani S, Nelson M, Ch'Ng C, Stone B, Wiselka M, Forton D, McPherson S, Halford R, Nguyen D, Smith D, Ansari A, Dennis E, Hudson F, Barnes EJ, Walker AS. Strategic treatment optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C. Wellcome Open Res 2021;6:93. [PMID: 34405118 DOI: 10.12688/wellcomeopenres.16594.2] [Reference Citation Analysis]
6 Simmonds P, Cuypers L, Irving WL, McLauchlan J, Cooke GS, Barnes E, Ansari MA; STOP-HCV Consortium. Impact of virus subtype and host IFNL4 genotype on large-scale RNA structure formation in the genome of hepatitis C virus. RNA 2020;26:1541-56. [PMID: 32747607 DOI: 10.1261/rna.075465.120] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 Cooke GS, Pett S, Mccabe L, Jones C, Gilson R, Verma S, Ryder SD, Collier JD, Barclay ST, Ala A, Bhagani S, Nelson M, Ch’ng CL, Stone B, Wiselka M, Forton D, Mcpherson S, Halford R, Nguyen D, Smith D, Ansari MA, Ainscough H, Dennis E, Hudson F, Barnes EJ, Walker AS; the STOP-HCV trial team. Variable short duration treatment versus standard treatment, with and without adjunctive ribavirin, for chronic hepatitis C: the STOP-HCV-1 non-inferiority, factorial RCT. Efficacy Mech Eval 2021;8:1-90. [DOI: 10.3310/eme08170] [Reference Citation Analysis]